Columns

Biohaven’s taldefgrobep alfa on FDA’s fast track

The U.S. Food and Drug Administration (FDA) has given fast track designation to Biohaven Pharmaceuticals‘ experimental medicine taldefgrobep alfa for the treatment of spinal muscular atrophy (SMA). The designation is granted to therapies that show potential in addressing serious conditions for which available treatments fall short. It…

Can I still take on an acting career with SMA?

My voice was off-pitch. I was too nervous. Though the casting directors for Singapore’s nationally televised talent show for children, “One Minute of Fame,” gave no obvious reaction, I realized the problem the second air left my lungs. Still, with all the boldness of an 8-year-old covered in makeup…

Tufts researcher wins MDA grant to study SMA treatment access

The Tufts Medical Center, a teaching hospital of the Tufts University School of Medicine, has been awarded a Muscular Dystrophy Association (MDA) grant to investigate patient access to treatments for spinal muscular atrophy (SMA) and other diseases. The project, led by James Chambers, PhD, will evaluate access…

In life with SMA, I’ve learned to go with the flow

Life doesn’t always flow the way it’s supposed to, and by “flow,” I mean literally. I’ve recently been experiencing a lot of issues with my nasojejunal (NJ) tube. It’s become more difficult to place each time it needs to be exchanged. It clogs much more easily…